Table 3 Correlations among biomarkers and demographic and clinical variables at first tofersen administration.
From: Neurodegenerative and neuroinflammatory changes in SOD1-ALS patients receiving tofersen
Biomarkers at baseline | Age at sampling rho (p-value) | BMI rho (p-value) | Time from onset to baseline rho (p-value) | ALSFRS-R score at baseline rho (p-value) | FVC at sampling rho (p-value) | DPR at baseline rho (p-value) |
|---|---|---|---|---|---|---|
CSF NfL | − 0.33 (0.19) | 0.04 (0.88) | − 0.91 (< 0.001) | 0.26 (0.31) | − 0.43 (0.16) | 0.80 (< 0.001) |
Serum NfL | − 0.54 (0.072) | − 0.06 (0.84) | − 0.91 (< 0.001) | 0.30 (0.33) | 0.02 (0.97) | 0.71 (0.011) |
CSF NfH | − 0.34 (0.18) | − 0.04 (0.86) | − 0.94 (< 0.001) | 0.22 (0.40) | − 0.43 (0.16) | 0.80 (< 0.001) |
Serum NfH | − 0.13 (0.68) | − 0.20 (0.52) | − 0.54 (0.07) | − 0.09 (0.79) | 0.06 (0.88) | 0.43 (0.16) |
CSF SerpinA1 | 0.13 (0.60) | 0.66 (0.80) | − 0.16 (0.53) | − 0.39 (0.12) | − 0.56 (0.06) | 0.44 (0.08) |
Serum SerpinA1 | − 0.26 (0.38) | 0.31(0.29) | − 0.35 (0.24) | − 0.02 (0.95) | − 0.64 (0.06) | 0.37 (0.21) |
CSF CHI3L1 | − 0.14 (0.61) | − 0.35 (0.18) | − 0.46 (0.07) | − 0.12 (0.67) | − 0.55 (0.07) | 0.58 (0.021) |
Serum CHI3L1 | 0.49 (0.12) | 0.46 (0.15) | 0.44 (0.18) | − 0.91 (< 0.001) | 0.08 (0.83) | − 0.16 (0.63) |
